

2024 Impact Report

aMoon is a global HealthTech investment fund headquartered in Israel on a mission to accelerate cure. With over \$1.3B AUM, aMoon is Israel's largest VC fund dedicated solely to HealthTech. We partner with outstanding entrepreneurs who harness groundbreaking science and technology to create lifechanging solutions. Together with our portfolio companies, we work tirelessly to advance solutions that help people live longer, better, healthier lives.

Table of Contents

04

Impact Engine
of HealthTech

10

aMoon in
Numbers

16

Accelerating Cure
Our Impact Thesis

25

Responsible Investing
Impact & ESG
Framework

31

Sourcing Engine

37

Investor
Additionality

40

Building & Nurturing
a Global HealthTech
Ecosystem

First Principles

MANAGING PARTNERS' FOREWORD



Yair Schindel, MD, MBA



Tomer Berkovitz, PhD

As we present our fifth annual Impact Report, we are focused on the core axiom that defines aMoon’s mission: accelerating cure. This principle is a guiding force that compels us to seek out and invest in technologies that redefine healthcare. It drives us to question convention, challenge inefficiencies, and build solutions from the ground up.

As Israel’s largest dedicated HealthTech investment house, we are driven to bring the future of healthcare closer to reality every day. With global healthcare needs growing increasingly complex, we remain committed to our belief that the convergence of innovation and medicine can deliver transformative outcomes. Each of our portfolio companies works towards

the goals of enhancing longevity and quality of life, driving scientific progress, and/or improving healthcare access and delivery.

From AI-driven diagnostics to breakthrough therapeutics and tech-enabled behavioral health solutions, our portfolio companies are creating real, measurable impact — in lives saved, conditions managed, and care accessed.

But impact doesn’t end with innovation. We believe that how we do business matters as much as what we do. As a signatory to the UN Principles of Responsible Investing (PRI), ESG principles are continuously evaluated within our practice as a lens through which we look at investments, manage internal processes, and support our portfolio

companies as we work together towards a healthier world.

In these pages, you’ll find a view of how we, together with our LPs, portfolio companies, and ecosystem partners, are building a future that allows people to live longer, better, healthier lives.

Thank you for being part of this journey.


With gratitude,
Yair & Tomer,
Managing Partners, aMoon Fund

Chapter 01

Impact Engine of HealthTech

Major scientific breakthroughs lay the foundations for a new era of innovation that is transforming the \$10T global healthcare industry

Transforming the way we diagnose, treat, and cure diseases across the continuum of care



2024 was a year of recalibration and quiet resilience for the healthtech sector.¹ While public market volatility and macroeconomic headwinds continued to ripple across global industries, private healthtech investment demonstrated a stabilizing trend, signaling a maturing market set up for long-term value creation.

After the contraction of 2022 and the cautious optimism of 2023, this past year marked a shift from reactive retrenchment to strategic deployment.² Investors, founders, and operators have begun to adjust to the “new normal,” one that rewards fundamentals, scalable business models, and measurable impact over short-term hype. In this environment, healthtech startups that demonstrated real-world clinical validation, regulatory progress, and sustainable unit economics were able to attract capital and continue building.

Private investment in healthtech remained below the 2021 peak but showed encouraging signs of resilience. Globally, funding levels stabilized across most subsectors, with digital health, diagnostics, and tech-enabled services leading the way. We observed a growing appetite for companies addressing cost containment, workforce optimization, and decentralized care delivery - solutions that speak to the systemic challenges faced by health systems worldwide.

Notably, 2024 also saw a resurgence in early-stage deal activity. While mega-rounds were fewer and more selective, seed and Series A rounds increased modestly, reflecting renewed confidence in the next wave of innovation. VCs, including aMoon, continued to execute rigorous diligence, prioritizing startups with proven clinical need, clear go-to-market strategies, and mission-aligned leadership teams.

AI and data-driven solutions remained dominant themes.³ The narrative has matured from hype to utility, with investors gravitating toward companies that embed AI in ways that augment, rather than replace, clinical workflows. This year saw significant progress in applications like clinical decision support, documentation, and personalized engagement. Importantly, there was also growing awareness of the ethical, regulatory, and security implications of health-related AI, driving a more thoughtful and standards-based approach to innovation.

1. Bessemer Venture Partners, State of Health Tech 2024
2. Silicon Valley Bank, Future of Healthtech 2024 Report
3. Galen Growth, Digital Health 2024 Funding and Key Trends



2024 Market Overview

Meanwhile, the convergence of healthcare and life sciences continued to blur traditional boundaries. Precision medicine, digital biomarkers, and tech-enabled solutions are increasingly seen not as niche categories but as core pillars of future healthcare delivery. Strategic collaborations between startups, pharma, and payers gained momentum, creating a more integrated ecosystem focused on outcomes and access.

Geographically, while the U.S. continued to lead in deal volume and maturity, Europe and Israel maintained strong momentum. Israel remained a global hub for translational innovation, especially in AI, medical devices, and digital health infrastructure, highlighting its strategic importance in the global healthtech landscape.⁴


While the industry seems to be on the upswing, it is impossible to know what lies ahead. The challenges facing the HealthTech ecosystem today require resolve, a clear strategic vision, and patient investors Who seek to exploit gaps between price and value over longer time horizons. If one holds the belief that innovative solutions that address the world's most pressing health challenges still create economic and societal value, then now is the time to invest in healthcare technology companies at deeply discounted prices relative to fundamental value.

In summary, 2024 was not a year of explosive growth, rather it was a year of re-grounding. The sector moved from exuberance to intentionality. For investors like aMoon, that's an opportunity to partner with bold, pragmatic entrepreneurs solving the healthcare system's most urgent challenges to help bring the future of health closer.


4. Israel Innovation Authority, Israel Life Sciences and Health-Tech Industry Report for 2024-25.



We Invest Across the Innovation Life Cycle



Israel is a Leading Global HealthTech & Innovation Hub



LEADING GLOBAL INNOVATION HUB

#1 IN THE WORLD IN RESEARCHERS PER CAPITA



LEADING INNOVATIVE HOSPITALS



UNIQUE DATASETS, SCALABLE PLATFORMS

CENTRALIZED & DIGITIZED HEALTHCARE SYSTEM



“START-UP NATION” LEADERSHIP IN DIGITAL TRANSFORMATION



Chapter 02


aMoon in Numbers

Our HealthTech Investment Platform

2017
Founded

Dedicated Platform
aMoon Alpha, IR & Communications,
Finance Compliance & Operations, Legal

30+
Portfolio
Companies



2
aMoon Locations
Ra'anana, Israel | Boston, MA




35+
Team
Members

8
Co-Investments



3
Investment Vehicles



\$1.3B
AUM

120+
Global
Limited Partners

aMoon Portfolio

We are proud to partner with innovators at the cutting edge of biology and technology, across HealthTech sectors, stages and geographies.

THERAPEUTICS



NASDAQ:ACET | EXIT





targeted therapies



























NASDAQ:VIRX

DIGITAL HEALTH





























NASDAQ:SOPH



M&A | Exit

TOOLS & DIAGNOSTICS



NASDAQ:AKYA









NASDAQ:SEER



NASDAQ:SERA



MEDTECH



M&A | Exit



aMoon Culture & Mindset

We are a team of scientists, physicians, entrepreneurs, and investors with global experience who work to advance solutions that will help people live healthier, better lives.

We firmly believe that collaboration among team members with a wide range of experiences generates more incisive and deeper insights that better serve our investors, portfolio companies and community.

Our commitment to these values is central to our core mission to accelerate cure. We recognize the value of varied perspectives in solving complex problems in a changing-and increasingly diverse world.

We aim to fulfill the following objectives to unleash the potential of a dedicated and committed mix of people:


- 

Enhance employee engagement and collaboration
- 

Recruit, develop and retain talented employees from all backgrounds and experiences
- 

Expand our impact and community engagement across HealthTech hubs around the globe


WORK EXPERIENCE



EDUCATION



LANGUAGE & CULTURE



GENDER

Our 2024 Investments

\$58.4 million

This past year, we invested in exciting new companies and continued to support our existing portfolio companies with additional investments as they progressed toward major milestones in their journey to accelerating cure.



conniehealth

AI-driven Medicare Advantage (MA) brokerage platform, empowering and scaling-up field agents



Hopscotch
Primary Care

Bringing a new level of primary care to rural communities




Air Doctor

Bringing a new level of primary care to rural communities



META SIGHT

Accurate, affordable, and accessible diagnostics with a single blood test



Coltac Therapeutics

Screening, discovering & developing molecular glues for protein degradation



Lyfegen

Value-based contracts for pharmaceutical companies



Better Life
PARTNERS

Novel care delivery platform to treat patients with substance use disorders (SUD)



ALTRUBIO

Precisely Restoring Immune Balance to Treat Autoimmune Diseases



scipher
MEDICINE

Transforming treatment in immunology



IMMUNITY RECRUITED

Multifunctional fusion immuno-therapeutics



AKOYA BIOSCIENCES
THE SPATIAL BIOLOGY COMPANY

Providing spatial phenotyping solutions to serve the needs of researchers



SOPHIA GENETICS

Democratizing Data Driven Medicine



prognomiQ

Reimagining early disease detection and treatment



MINA Therapeutics

Activating RNA, mastering disease

Our Investment Impact

\$3.2 billion

Was raised by our portfolio companies in the public and private rounds during and after our initial investment



Chapter 03

Accelerating Cure

Our Impact Thesis

At aMoon, we believe that creating long-lasting impact and sustainable value is deeply connected to our ability to advance technologies that help people live healthier, longer, and better lives.



Impact Pillars

We believe everyone deserves better access to better healthcare.

We work to identify and fund transformative solutions that tackle healthcare’s most pressing challenges while simultaneously producing value for our stakeholders.

Our impact assessment manifests across the entire investment cycle; from screening, through investing, to actively monitoring our portfolio.

We have defined five impact pillars that derive from our mission to accelerate cure:

Save & extend lives

We back innovations that can cure diseases and save lives through breakthrough treatment mechanisms.

Improve quality of life

We don’t just aim to keep people alive longer, but also to improve the quality of life for those with acute or chronic diseases.

Increase access to care

We support solutions aiming to democratize healthcare and ensure access to affordable, quality health services for all.

Reduce costs













As healthcare costs rise to unsustainable levels, we focus on technologies that increase institutions’ capacity and cut costs.

Enable breakthrough discoveries

We promote the development of groundbreaking technologies that transform the way we diagnose and treat disease.



















Innovation Index

VELOCITY

COMPANY	SAVE & EXTEND LIVES	IMPROVE QUALITY OF LIFE	INCREASE ACCESS TO CARE	REDUCE COSTS	ENABLE SCIENTIFIC BREAKTHROUGHS
 Breeot CLINIC					
 cAVos Biotechnologies					
 Coltac Therapeutics					
 eleos					
 GraphiteRx					
 IBEX					
 lin					
 LUTRIS					
 Lyfegen					
 METASIGHT					
 NECTINTx					
 Satellite ^{BIO}					

Innovation Index

GROWTH I & II

COMPANY	SAVE & EXTEND LIVES	IMPROVE QUALITY OF LIFE	INCREASE ACCESS TO CARE	REDUCE COSTS	ENABLE SCIENTIFIC BREAKTHROUGHS
 Air Doctor					
 ALTRUBIO					
 AKOYA BIOSCIENCES <small>THE SPATIAL BIOLOGY COMPANY</small>					
 Better Life PARTNERS					
 BioLogic Design					
 conniehealth					
 Hopscotch Primary Care					
 KAR					
MDCLONE					
 META SIGHT					
 MiNA Therapeutics					
 MOBILion SYSTEMS, INC. <small>Rewriting What Others Learn About</small>					
 omada					
 prognomiQ					
Satellite ^{BIO}					
 scipher MEDICINE					
 seer					
 SERA PROGNOSTICS <small>The Prognosis Company</small>					
 SOPHIA GENETICS					
theranica					
 ULTIMA GENOMICS					



HEALTH PROGRAMS BUILT JUST FOR YOU

According to the American Heart Association, 29.3 million people in the U.S. live with diagnosed diabetes, with another 9.7 million estimated to have undiagnosed diabetes. A staggering 115.9 million have pre-diabetes¹. The long-term effects of diabetes include damage to large and small blood vessels, which can lead to heart attack and stroke, and problems with the kidneys, eyes, feet and nerves.

Omada Health addresses this prevalent problem by helping individuals living with chronic conditions like prediabetes, diabetes, and hypertension, achieve long-term health improvements. Combining the latest clinical protocols and breakthrough behavioral science, Omada is a virtual-first healthcare provider that nurtures lifelong health, one day at a time.

Working with over 1,900 enterprise customers, including Fortune 500 and small- and medium-sized employers, health plans, and health systems, Omada delivers personalized interventions for people living with chronic conditions.

Omada’s virtual care programs are clinically supported and evidence-based, and it shows - people don’t just try, but stick with the programs, resulting in long-term changes in health behavior, reduced healthcare costs and increased ROI.

Leveraging clinical results and technology, Omada amplifies and extends the influence of their real human care teams, from health coaches to clinical specialists, helping people reach lasting change.

SAVE & EXTEND LIVES

1M+
Member Enrollments

Every 2 min
A gratitude message is sent from a member to their Omada care team

25M+
Messages sent

1. Martin et. al. 2024 Heart disease and stroke statistics: a report of U.S. and global data from the American Heart Association. Circulation. Published online January 24, 2024. doi: 10.1161/CIR.0000000000001209

theranica

DRUG-FREE PAIN RELIEF

Sivan Ironi had her first migraine at age 14, leading to a frustrating and painful journey of one ineffective treatment after another. Alon Ironi, watching his daughter suffer from migraine, decided to dedicate himself to the discovery of a non-pharmacological option to treat migraine. Utilizing his training in electrical engineering, he, along with trusted colleagues, developed Nerivio®.

Nerivio, a digital therapeutic, harnesses an innate pain inhibition mechanism known as Conditioned Pain Modulation (CPM), which is our bodies' endogenous way of regulating multiple painful stimuli. Using non-painful Remote Electrical Neuromodulation (REN), Nerivio triggers stimulation of peripheral nerves and activates the CPM. Once activated, the CPM pathway releases certain neurotransmitters in the brain stem that can shut down the pain.

Nerivio is the first and only REN wearable that harnesses the natural power of the brain to block migraine symptoms without the use of medication. With early intervention being key, Nerivio offers a safe and side-effect-free alternative, empowering people to take control of their health and providing a foundation for complete migraine care.

While Nerivio was inspired by one girl with migraine, this idiopathic pain condition affects over 1 billion people worldwide, making it one of the top causes of disability and imposing immense personal, economic, and social burdens. These debilitating headaches cause severe pain, making it difficult to work, enjoy hobbies, or even take care of basic needs.

Nerivio is FDA-cleared and CE-marked for the acute and/or preventive treatment of migraine with or without *aura* in people 8 years of age or older. It has been used in more than 650,000 migraine treatments in the US, including adolescents and veterans living with migraine.

IMPROVE QUALITY OF LIFE


39 million
AMERICANS LIVE WITH MIGRAINE

7 OUT OF 10
PATIENTS ACHIEVED PAIN RELIEF WITH NERIVIO



23%
OF PATIENTS ACHIEVED HIGHER RELIEF THAN WITH MEDICATION

9 OUT OF 10
PATIENTS DEMONSTRATED SUSTAINED PAIN RELIEF AND PAIN FREEDOM AT 24 HOURS



SENIOR PRIMARY CARE, POWERED BY RELATIONSHIPS

24.4% of the U.S. population live in rural areas,¹ or almost 20 million people. According to the CDC², rural residents face higher risk of death due to factors like limited access to specialized medical care and emergency services, and exposure to specific environmental hazards.

Hopscotch is addressing this challenge with its tech-enabled primary care delivery service, with an initial focus on expanding access and care for Medicare and Medicare/Medicaid patients in underserved, rural communities.

On a mission to transform lives in rural communities through accessible and proactive value-based care, Hopscotch is committed to delivering exceptional care for seniors, both in clinics and beyond, supporting patients with more resources, time, and the attention of a full care team.

Hopscotch specializes in serving the needs of patients with Medicare, including most Medicare Advantage plans, Original Medicare Part B, Medicare Supplement or Medigap plans, and Medicare/Medicaid Plans.

Understanding the importance of building a community of care centered around the needs of patients, Hopscotch strives to support patients, care team members, and other partners within the healthcare community.

Hopscotch is currently the largest provider of healthcare in Western North Carolina, with 11 clinics and serving approximately 12k patients.

INCREASE ACCESS TO CARE

~20M

Americans live in rural areas

30%

Of individuals 65+ in the US are diagnosed with diabetes

47%

Of individuals 65+ in the U.S. are diagnosed with arthritis

1. FHFA Insights: Who Lives in Rural America?, Dec, 2024
2. CDC: Rural Health, May 2024



**ENABLING ACCESS TO CUTTING-EDGE MEDICINE THROUGH
VALUE-BASED CONTRACTING**

Recent innovations in personalized and specialty therapies have delivered on their promise to be the next generation of life-changing medicine. Unfortunately, their high cost and clinical uncertainty remain significant access barriers. Value-based contracts (VBCs) are contracts between payers and manufacturers that tie drug prices to clinical success. While VBCs can serve as a solution to this challenge of access, they have not yet been adopted at scale because (1) contracting parties are unfamiliar with the innovative contracting process and (2) the parties lack the technological tools to overcome the intense administrative burden of tracking and executing agreements.

Lyfegen, a Switzerland-based company, is catalyzing the value-based care revolution with its software platform that enables outcome-based contracting for pharmaceuticals. By simplifying access, pricing, and rebate management, Lyfegen empowers health insurers, governments, hospital payers, and pharmaceutical companies worldwide to reduce the administrative burden of complex drug pricing agreements, improve patient access to innovative therapies, and extract greater value from these contracts.

REDUCE COSTS

€70M

Additional rebates found

90%

Time saved

€200M

rebates managed

2000+

**Drug rebate
agreements managed**



ENABLE SCIENTIFIC BREAKTHROUGHS

UNLEASHING THE POWER OF GENOMICS AT SCALE

In April 2003, 50 years after Watson and Crick first described the chemical structure of DNA, the DNA sequence that makes up the human genome was proclaimed "essentially complete." The cost of sequencing the first human genome was about \$3 billion, and it took several international institutes, hundreds of researchers and 13 years to complete. Since then, the cost has decreased to \$1,000 and continues to drop as the technology matures.

Whole genome sequencing helps scientists decipher genetic causes of disease, better understand diseases, improve diagnoses, and develop more effective medicines than ever before. It allows researchers to assess the cumulative risk from many genetic variants which together can have dramatic effects on disease risk to more easily identify individuals who have a genetically higher risk for a particular disease or trait. The early identification of at-risk individuals for certain diseases can guide preventative measures.

Ultima Genomics is continuously driving the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change, and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to under \$100, helps overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information.

The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century.

\$80

COST OF
GENOME SEQUENCING

300,000+

GENOME READS PER YEAR



50%

INCREASE IN THROUGHPUT

5X

IMPROVEMENT IN YIELD

Chapter 04

Responsible Investing

Our ESG Framework

Integrating ESG into our practices & Investment Lifecycle

Striving for continuous improvement

At aMoon, we seek to integrate environmental, social, and governance (ESG) considerations into our daily operations as well as into our investment process, in line with industry guidance and best practice standards. By examining the policies and practices of potential portfolio companies to adhere to these values, we maximize impact while mitigating risk.

We also monitor our portfolio's ESG progress to identify gaps and value creation opportunities. Our dedicated team is available to work with each company to improve ESG adherence.

Since 2022, we have been a proud signatory to the UN PRI, the largest global reporting project on responsible investment, putting responsible investing into practice and contributing to the development of a more sustainable global order. This year we submitted our first Private Transparency Report, in which we reported information about our investment processes and internal and external ESG practices.



ENVIRONMENT

- Environmental impact
- Climate change & business
- Model resilience



SOCIAL

- Diversity & inclusion
- Human Capital development & corporate culture



GOVERNANCE

- Corporate governance
- Board governance
- Cyber & data privacy

Portfolio Impact & ESG Survey

As part of our mission to accelerate cure and tackle healthcare’s most recalcitrant challenges, Impact & ESG are an integral part of our mission. To this end, we conduct a bi-annual survey to evaluate the state of our active private portfolio companies’ contribution to our Impact values.



Measuring Impact

77%

Measure impact outcomes

88%
Growth

54.5%
Velocity

19%

Have a team member dedicated to ESG oversight and implementation

Examples of measurement methods:

aMoon 2024 Impact Report



Clinical Outcomes



Research



ROI Evaluations



Sequencing Cost



Reimbursement & Payer Adoption



Physician and Patient Satisfaction



Health KPIs



Patient Engagement & Satisfaction



Environmental Impact

66%

Take actions to **minimize the environmental impact** of physical operations

88%

Growth

54.5%

Velocity

Social Impact

In 2024, our portfolio companies collectively:

Treated

>782,000

Patients



Operated in

>21,830

Hospitals / academic institutions / clinics



Employed

>3,100

People worldwide



“Use a 3rd party service provider to manage chemical disposal and gas management”



“Improve waste efficiency, require onsite waste recycling”



“Constantly working to reduce footprint of operation and streamline packaging and other reductions to save materials, cost and time”



“We have paperless operations and choose suppliers that prioritize environmental responsibilities”




“Recycling, low impact supplier selection, energy usage and other similar methods”

Social Impact continued

56%

Have a policy in place for **Diversity & Inclusion**




Governance

Information Security Management

89%

Have policies or procedures in place designed to safeguard the **privacy of information** shared by employees, customers, and/or clients




82%

Have initiatives in place for **staff's personal and professional development**



78%

Have a corporate code of **ethics / good business conduct** policy in place



Have programs in place or in development to comply with **privacy laws** applicable to their business



Chapter 05

Sourcing Engine

Proactive & Thematic Approach to Sourcing


DEEP COLLABORATION WITH TOP VCs, _____
PROPRIETARY GLOBAL NETWORK with meaningful connections
across tens of thousands of organizations and institutions

COLLABORATIONS WITH MAJOR PHARMA, _____
STRATEGICS & ACADEMIC INSTITUTIONS
to match real market needs with promising innovations:



ENTREPRENEUR IN RESIDENCE (EIR) PROGRAM _____
for seasoned tech entrepreneurs, embedding them
into our team & supporting them in developing
new HealthTech ventures

THEMATIC EFFORT & DEEP EXPERTISE _____
aMoon’s Spikes Program fuels our team’s continuous
learning to explore and get us ahead of the curve in
the most exciting and disruptive fields



Our Investment Sourcing Engine

Extensive footprint in Israel and strong global network generating almost 10,000 investment opportunities since inception

Proactive & reactive deal flow

Referrals from global network of venture partners and advisors

Entrepreneur In Residence (EIR) Program

High quality syndication opportunities from top international funds

Collaborations With Major Pharma, Strategics & Academic Institutions

STARFINDER LAB
In partnership with Roche

bing
פינה
WEIZMANN
INSTITUTE
OF SCIENCE

LEAP
In partnership with Microsoft

Baker
HEART & DIABETES INSTITUTE

9,779
Leads

1,087
Diligence


40*
Investments

* 2 investments made in H1 2025


aMoon Deal Flow Funnel

2019 – EOQ4-2024


Velocity Deal Flow Funnel




Growth Deal Flow Funnel



Deal Flow Segmentation by Geography



Deal Flow Segmentation by Sector



Demonstrated Track Record in Venture Formation

aMoon builds companies around groundbreaking platform technologies.

We identify these technologies through proactive engagement with leading research and tech centers and provide them with critical support services including talent placement, fundraising, and strategy.

Breeot
CLINIC

A modern health clinic focused on preventative, proactive, and personalized primary care

CAVOS
Biotechnologies

Proprietary comparative genomics algorithms to discover and develop novel mRNA therapeutics for cancer and other diseases

Coltac
Therapeutics

A cost-effective, positive signal, e. coli-based system to discover and develop novel molecular glues for targeted protein degradation

lin

The first truly digital pain care clinic enabling remote care

METASIGHT

Multi-omic diagnostic tests for various diseases discovered using proprietary, unbiased, high throughput Mass Spec analyses of a population-scale biobank

NECT NTx

Biopharmaceutical company developing multiple first- and best-in-class immune checkpoint inhibitors and ADCs

Satellite^{BIO}

Implantable satellite matrices as living therapeutic solutions for patients who suffer from serious liver diseases

Chapter 06

Investor Additionality

We Measure our Investor Additionality

aMoon Alpha, our internal value creation team, works directly with our portfolio companies to help them succeed

Bridges & Strategics

240+

Introductions to strategic Pharma & Diagnostic companies

450+

Introductions to funds for next round financing

160+

Introductions of our portfolio companies to payors and providers in the U.S.

20+

Global events hosted by aMoon bringing together key decision makers from across the HealthTech Ecosystem

Capital

\$100M+

Raised by portfolio companies from our direct introductions

\$300M+

Followed aMoon investments

PR Support

The New York Times

TIME

BUSINESS INSIDER

STAT

FIERCE Healthcare

WSJ

Talent

140+

Connections made for Leadership, Board & Advisor placements in portfolio companies

Testimonials from our Portfolio Companies

Business Development & Strategy

“Extremely helpful for investor & potential business partner/customer introductions, as well as strategic restructuring of primary business model”

“We have received - much appreciated - support with regard to all of the above: including BD strategy, intros, fund raising, and communications, etc”

“aMoon has provided a variety of helpful advice and suggestions in regards to our business development and strategic activities”

“We continuously elaborate on when to go in which market. Esp. the conversation towards the US market (go to market, timing, how) are very helpful”

Financing & Building Syndicates

“aMoon has introduced and continued to introduce us to potential investors”

“aMoon has introduced us to dozens of potential investors”

“Made introduction to VCs in our Series B raise and provided reference for the management team”

“Multiple introductions to pharma partners and investors”

Talent Placements & Introductions

“Referred & introduced potential candidates to us”

“Interim Head of People was from link provided by aMoon”

“Ongoing coaching and support to our HR manager”

Communications, Storytelling & PR

“aMoon has been a great partner for us in developing strategy, finding potential partners and building our story”

“We have received support from aMoon on Storytelling (telling our financial story to investors)”

“aMoon has provided us with valuable introductions to investors, help with PR, valued thought partner”

R&D Strategy & Operations

“As part of the board, the aMoon representative provided meaningful advice and strategy”

“aMoon has made introductions to technology platforms that have helped us broaden our understanding of current market offerings”

“Highlighting of interesting proteomic companies and providing introductions to management teams as warranted”

Chapter 07

Building & Nurturing a Global HealthTech Ecosystem

Collaborations & Partnerships




StarFinder Digital Innovation Lab is an exclusive early-stage collaboration program powered by aMoon and Roche. Now in its 4th year, StarFinder assists early-stage ventures developing highly disruptive AI-based technologies in diagnostics to reach Proof of Concept. Initially focused on Israel, the program has since expanded to Boston, Singapore, Australia and South Korea – building bridges between vibrant HealthTech hubs around the world and creating opportunities for collaboration.



Entrepreneur in Residence (“EIR”) Program

Our EIR program selects a small number of seasoned entrepreneurs every year for a six-month residency period. During that time, we provide them with access to the Fund’s diverse activities, from deal flow meetings to diligence sessions and weekly portfolio reviews. We also help connect them with experts in our network. We work with them as they explore different ideas for new ventures and may ultimately choose to invest if they pursue a new venture that is aligned with aMoon’s strategy.



LEAP

Medtronic

Microsoft

8200Bio

BMC Innovation
Bellson Future of Health

A first-of-its-kind program that brings together tech talent and practicing clinicians to form the next wave of HealthTech startups.

Empowers promising entrepreneurs and physicians to explore and create revolutionary solutions to unmet needs in the healthcare ecosystem.



The Innovation Fellows Program, held in collaboration with The Baker Institute in Australia and aMoon, is designed to cultivate commercial and entrepreneurial thinking among graduate students, postdocs, and young faculty working at the intersection of science and healthcare innovation. Along with leading academic institutions, the semi-virtual program combines bi-weekly sessions, mentorship from aMoon’s expert team, and a final in-person workshop and venture competition. Participants gain hands-on experience in evaluating academic technologies, building development and business plans, assessing IP and market potential, and understanding venture formation. The program aims to accelerate the translation of breakthrough academic research into impactful, real-world healthcare solutions.



Driving Change in the Israeli HealthTech Sector



8400 The Health Network is a nonprofit organization founded in 2017 that leverages Israel's human and digital assets to accelerate global cure and build a powerful growth engine for the country. Recognizing the nation's robust digital healthcare infrastructure and culture of innovation, 8400 seeks to harness these assets to accelerate global cures and enhance national well-being. The organization focuses on bridging critical gaps within the ecosystem, such as talent development, policy and regulation, technology transfer, funding, data collaboration, and infrastructure, by fostering cross-sector collaboration among leaders from academia, industry, government, and healthcare providers.

Central to 8400's approach is its flagship Leadership Program, conducted in partnership with Harvard Business School, which annually brings together cohorts of senior Israeli HealthTech leaders for a seven-month fellowship. This program cultivates a network of over 400 professionals who engage in peer learning and collaborative projects aimed at driving systemic change. Additionally, 8400 operates initiatives like the Programs Incubator, which supports ecosystem growth projects, and the Women Executive (WE) Launchpad, designed to elevate women into executive roles within the HealthTech sector. Through these efforts, 8400 is instrumental in transforming Israel into a globally connected HealthTech powerhouse.



WE@HealthTech is a launchpad program that aims to promote women managers to C-level executive positions throughout the Israeli ecosystem and build their skills for successful executive careers.

Over the eight-month period, the program accelerates personal and professional growth, while stimulating significant career progression and multiple meaningful collaborations.



Chamal VC

Chamal VC was established by a dedicated group of VCs to support CEOs navigating times of conflict and uncertainty.

Working collaboratively with industry partners, this initiative takes a full-scale and holistic approach to consultation, services, and support, to ultimately promote entrepreneurial resilience.

Connecting HealthTech Innovators Globally

2024 Events Timeline

JPM CEO Network



New Horizons in Metabolic Disorders



BioMed



Journey



Immunology Boston



Spotlight on Medtech Strategic Relationships



Q1

Q2


Q3

Q4

ARC Visit Boston



Mixiii



Diagnostics Boston event



Baker




ARC Happy Hour aMoon<>UST



Startup Foundation



Portfolio Companies in the News



AltruBio, after tweaking checkpoint drug, raises \$225M for midphase ulcerative colitis program

[READ MORE](#)



Women Can Now Order a Blood Test to Predict Preterm Birth

[READ MORE](#)



JPM24: Amazon rolls out digital health benefits program, taps Omada Health as launch partner

[READ MORE](#)



Air Doctor lands \$20 million Series B to connect travelers and doctors

[READ MORE](#)




Ultima Genomics launching high-end DNA sequencers that can read genome for \$100

[READ MORE](#)



Review of Dr Reddy's Nerivio Migraine Device: Medication-free headache relief

[READ MORE](#)



Exclusive: Lin Health partners with Mayo Clinic

[READ MORE](#)



Disclaimer

This presentation (including all information contained herein) is being delivered to parties for the purposes of learning about aMoon's impact. It is provided on a confidential basis to allow readers to learn more about aMoon (the "Fund").

This presentation is being provided to you for the sole purpose of affording you with background information about the Fund's business. Neither the presentation nor anything contained herein forms the basis of any contract or commitment. This presentation does not purport to be all-inclusive or to contain all the information that a prospective investor may desire in investigating the Fund. This presentation does not purport to summarize all of the conditions, risks, and other attributes of an investment in the Fund and is qualified in its entirety by the information to be made available by the Fund to persons meeting certain investment criteria and not to the public in general.

It is hereby clarified that the offering of interests in the Fund is a private offering and does not constitute and is not intended to constitute an "offer to the public" as defined in the Israeli Securities Law 5729-1968 (the "Israeli Securities Law"), and the interests have not been registered nor is there an intention to register them, under the Israeli Securities Law, or under the laws of any other jurisdiction. Investors in the interests will not be able to rely on such securities law in many matters related to or deriving from their investment in the Fund. The interests will be offered and sold under exemptions provided by the Israeli Securities Law in connection with the foregoing, therefore the offering and sale of securities in the Fund to investors that do not fall under the categories of Section 15a(b) of the Israeli Securities Law will be limited to 35 investors in any 12-month period. Neither the Israeli Securities Authority nor the regulatory authority of any other country, state or jurisdiction has approved or will approve this presentation or the interests referred to herein. Any representation to the contrary is unlawful.

Neither the General Partner nor the management company, intend to register as an investment adviser, an investment marketer or an investment portfolio manager under the Israeli Regulation of Investment Advice, Investment Marketing and Investment Portfolio Management Law, 5755-1995, and neither of them carries insurance as set forth under the aforesaid laws. Nothing in this presentation constitutes legal, accounting or tax advice or individually tailored investment advice. It is further clarified that the interests in the Fund are not being registered under the U.S. Securities Act of 1933. The interests are being offered in a private placement and each investor will be required to make certain representations, including but not limited to (a) that it is an accredited investor as defined in Regulation D under the Securities Act, (b) that it is acquiring an interest in the Fund for its own account, for investment purposes only and not with a view to its distribution, and (c) that it has received or had access to all information it deems relevant to evaluate the merits and risks of the prospective investment. This presentation is not intended for, and does not constitute an offer to sell or the solicitation of an offer to buy, any interests in the Fund, to any person to whom such an offer or solicitation is unlawful or not authorized.

While we have endeavored to ensure that all data herein is accurate, no representation, express or implied, is made as to the accuracy, completeness or correctness of information contained in this presentation, including the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in the presentation ("Forward Looking Statements"). Such Forward Looking Statements are by their nature subject to significant uncertainties and contingencies and are based upon a number of estimates and assumptions that are subject to change (and in many cases are outside the control of the Fund and its managers and general partner).

By participating in this presentation or by retaining a copy of this presentation, you agree to be bound by the foregoing limitations. This presentation (including all information contained herein) is being delivered on a confidential basis.

The presentation is the property of the Fund and no part of the presentation may be disclosed, distributed or reproduced to any third party without the consent of the Fund. The offering of interests in the Fund is a private offering and is not intended to constitute an "offer to the public" as defined in the Israeli Securities Law 5729-1968 (the "Israeli Securities Law"), therefore the offering and sale of securities in the Fund to investors that do not fall under the categories of Section 15a(b) of the Israeli Securities Law will be limited to 35 investors in any 12-month period. This presentation does not constitute an offer to invest in the Fund.

This document is issued by aMoon Ventures Y. SH. Ltd Company number 515563377 (aMoon) as a Corporate Authorised Representative (AR No. 001292024) of Polar 993 Advisory Pty Ltd (ACN 649 554 932) (AFSL 531197) (Polar Advisory). aMoon's authority under its Corporate Authorised Representative Agreement with Polar Advisory is limited to general advice regarding the aMoon Growth Fund II L.P. only to wholesale clients. This document is provided on a confidential, personal and private basis for use only by the recipient as a wholesale client under the Corporations Act 2001 (Cth) and should not be forwarded to others. The information contained in this document is of a general nature only and is not to be taken to contain any financial product advice or recommendation. Nothing in this document is intended as financial product advice and it does not take into account any person's investment objectives, financial circumstances or specific needs. This document is neither an offer to sell nor a solicitation of any offer to acquire interests or any other investment and should not be used as the basis for making an investment in the aMoon Growth Fund II L.P. aMoon and Polar Advisory and their directors, officers, employees, agents or associates do not guarantee repayment of capital, the performance of any fund or any service. Past performance is not a reliable indicator of future performance.